Emerging evidence from clinical trials and observational research showing the additive benefits of combining SGLT2i and GLP-1RA, including evidence from the present study, suggests that the addition of GLP-1RA can provide further metabolic and cardiorenal risk reductions in those who are not achieving treatment goals with SGLT2i alone
For example, when a model amphipathic peptide (Ac-Gly-Ala-Glu-Lys-Ala-Ala-Lys-Glu-Ala-Glu-Lys-Ala-Ala-Lys-Glu-Ala- Glu-Lys-amide) was designed, and its alpha-helical content was measured using CD and 2D-NMR spectroscopies, it was shown to contain 65% alpha-helical structure [69]
For best results, take the capsule consistently at the same time each day
For people currently managing obesity and who are not yet on treatment or who are on GLP-1 therapy but not achieving their desired outcomes the most appropriate step is a conversation with a qualified healthcare professional
The clinical records management system the practice uses must capture this reasoning at the point of care, not during a retrospective audit response
Even though our oxidative toxic load increases as we age, the breakdown of cellular health and increased risk of disease and disfunction is NOT inevitable